Nuovo G J, Babury R, Calayag P T
Department of Pathology, SUNY, Stony Brook.
Mod Pathol. 1991 Sep;4(5):632-6.
Little is known about the host's immunological response to human papillomavirus (HPV) infection, which is an important co-factor in genital tract cancers. This study analyzed the HPV type in pre- and posttreatment tissues in immunocompromised women with cervical squamous intraepithelial lesions (SILs) that recurred after ablative therapy. The HPV type was the same in the pre- and posttreatment lesion in nine of 12 recurrent SILs in women immunocompromised because of AIDS or long-term immunosuppressive therapy. In an extension of a previous study, it was noted that a different HPV type was present in the posttreatment SIL when compared to the pretreatment lesion in 13 of 14 cases in immunocompetent women. These observations support the hypothesis that a type-specific resistance may develop after ablative treatment, preventing re-infection by the same HPV type in immunocompetent women.
关于宿主对人乳头瘤病毒（HPV）感染的免疫反应知之甚少，而HPV感染是生殖道癌症的一个重要协同因素。本研究分析了免疫功能低下的宫颈鳞状上皮内病变（SIL）女性患者在消融治疗后复发的治疗前和治疗后组织中的HPV类型。因艾滋病或长期免疫抑制治疗而免疫功能低下的女性中，12例复发性SIL中有9例的治疗前和治疗后病变中的HPV类型相同。在先前研究的扩展中，发现免疫功能正常的女性中，14例中有13例的治疗后SIL与治疗前病变相比存在不同的HPV类型。这些观察结果支持这样一种假设，即消融治疗后可能会产生型特异性抗性，从而防止免疫功能正常的女性被同一HPV类型再次感染。
